Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Capecitabine
Drug ID BADD_D00349
Description Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Indications and Usage For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
Marketing Status Prescription
ATC Code L01BC06
DrugBank ID DB01101
KEGG ID D01223
MeSH ID D000069287
PubChem ID 60953
TTD Drug ID D00HCQ
NDC Product Code 72205-007; 69097-948; 59923-722; 59651-204; 0378-2511; 55111-893; 55111-496; 0054-0272; 72205-006; 70756-816; 50268-154; 51407-095; 15308-0714; 16714-467; 62756-239; 67877-458; 64980-277; 55512-0015; 16729-072; 68001-487; 67877-459; 55111-497; 51079-510; 35369-0010; 54893-0002; 70756-815; 63482-099; 60687-149; 0004-1101; 62331-043; 72485-205; 53183-4009; 69539-019; 0004-1100; 65162-843; 16729-073; 72969-094; 62756-238; 16714-468; 68554-0033; 69097-949; 54245-7014; 72485-204; 62756-088; 0054-0271; 59651-205; 0093-7473; 72606-555; 76302-001; 69539-020; 65162-844; 53104-7618; 0378-2512; 51407-096; 81955-0001; 63759-0001; 49452-1713; 68001-488; 65129-1241; 64980-276; 0093-7474; 72606-554; 59923-721
Synonyms Capecitabine | N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine | Xeloda
Chemical Information
Molecular Formula C15H22FN3O6
CAS Registry Number 154361-50-9
SMILES CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cholangitis09.02.01.0020.002931%Not Available
Cholecystitis09.03.01.0010.001865%
Cholecystitis acute09.03.01.0030.000799%Not Available
Cholelithiasis09.03.01.002--Not Available
Cholestasis09.01.01.001--Not Available
Chromaturia20.02.01.0020.001865%
Circulatory collapse24.06.02.0010.000695%Not Available
Clostridium difficile colitis11.02.02.004; 07.19.01.0040.001066%Not Available
Coagulopathy01.01.02.0010.002131%Not Available
Colitis07.08.01.0010.010124%
Colitis ischaemic24.04.08.012; 07.08.01.0040.002131%Not Available
Colitis ulcerative10.02.01.004; 07.08.01.005--Not Available
Colon cancer16.13.01.001; 07.21.01.0010.001737%Not Available
Coma17.02.09.001--Not Available
Coma hepatic17.02.09.002; 09.01.03.005--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Congenital anomaly03.02.01.001--Not Available
Conjunctivitis11.01.06.012; 06.04.01.0020.001066%
Constipation07.02.02.001--
Coordination abnormal17.02.02.0040.000799%Not Available
Corneal erosion06.06.03.0030.001066%Not Available
Coronary artery disease02.02.01.001; 24.04.04.006--Not Available
Coronary artery occlusion24.04.04.013; 02.02.01.006--Not Available
Cough22.02.03.001--
Creatinine renal clearance decreased13.13.01.013--Not Available
Crohn's disease10.02.01.005; 07.08.01.0150.002131%Not Available
Crying17.02.05.013; 12.02.11.001; 08.01.03.005; 19.04.02.002--Not Available
Cyanosis24.03.01.007; 22.02.02.007; 02.01.02.002--
Cyst16.02.02.002; 08.03.05.001--Not Available
Cystitis11.01.14.001; 20.03.02.0020.003197%
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 35 Pages